Michael Findura, DO
Internal Medicine · Wall Township, NJNPI 1922072420
Payments from drug & device makers
Across 437 payments — averaging $12.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$652
- Amgen$392
- GSK$298
- Novo Nordisk$279
- Corcept Therapeutics$261
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,260100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 163 | $1,435 |
| AstraZeneca | 43 | $652 |
| Amgen | 26 | $392 |
| GSK | 20 | $298 |
| Novo Nordisk | 20 | $279 |
| Corcept Therapeutics | 18 | $261 |
| Pfizer | 22 | $191 |
| Johnson & Johnson | 19 | $172 |
| Novartis | 11 | $160 |
| Exact Sciences | 9 | $157 |
| Boehringer Ingelheim | 9 | $131 |
| Bayer | 8 | $124 |
| Lundbeck LLC | 6 | $98 |
| Kowa Pharmaceuticals America, Inc. | 7 | $97 |
| Lilly USA, LLC | 6 | $92 |
| Abbott | 6 | $90 |
| Acella Pharmaceuticals, LLC | 4 | $72 |
| Tolmar, Inc. | 5 | $70 |
| Merck | 5 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| Genentech USA, Inc. | 3 | $43 |
| IBSA Pharma Inc. | 3 | $43 |
| Amarin Pharma, Inc. | 3 | $40 |
| Eisai Inc. | 3 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $40 |
| Currax Pharmaceuticals LLC | 3 | $38 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Halozyme Inc | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $13 |
How this compares
$5,265 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $110,735 |
| OzempicSemaglutide | 62 | $96,203 |
| JanuviaSitagliptin Phosphate | 89 | $87,925 |
| XareltoRivaroxaban | 72 | $80,333 |
| JardianceEmpagliflozin | 45 | $55,760 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $43,944 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $39,304 |
| MounjaroTirzepatide | 21 | $37,379 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $27,785 |
| RybelsusSemaglutide | 13 | $15,253 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $13,006 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $12,562 |
| SynthroidLevothyroxine Sodium | 114 | $11,719 |
| FarxigaDapagliflozin Propanediol | 16 | $10,321 |
| Icosapent Ethyl | 21 | $10,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $67 | $131,869133 claims |
| Novo NordiskOzempic, Rybelsus | $279 | $111,45775 claims |
| PfizerEliquis | $191 | $110,735100 claims |
| Johnson & JohnsonXarelto | $172 | $80,33372 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $298 | $67,08994 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $131 | $61,58156 claims |
| Lilly USA, LLCMounjaro | $92 | $37,37921 claims |
| AbbVieSynthroid | $1,435 | $11,719114 claims |
| AstraZenecaFarxiga | $652 | $10,32116 claims |
| NovartisEntresto | $160 | $9,94015 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $97 | $4,46917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Wall Township
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.